At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 667 enrolled
Drug / intervention
Azelaic acid foam +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
In Brief
A Phase 3 clinical trial evaluating Azelaic acid foam and Azelaic acid foam - Placebo for Rosacea. Completed, enrolled 667 participants across 1 site.
Detailed Summary
To compare the bioequivalence of Perrigo's azelaic acid foam product to Finacea Foam for the treatment of Inflammatory Lesions of Rosacea
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
CollaboratorsDPT Laboratories, Ltd.
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 2016
Enrollment StartNov 2016
Primary CompletionOct 2017
TodayJul 2026
First PostedJun 15, 2016
Enrollment StartNov 1, 2016
Primary CompletionOct 1, 2017
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.0 years ago
Interventions
Azelaic acid foamdrug
Azelaic acid foamdrug
Azelaic acid foam - Placebodrug